BIOA (Bioage Labs) Net Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Bioage Labs's Net Income for the three months ended in Dec. 2024 was $-21.13 Mil. Bioage Labs's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Bioage Labs's net margin for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Bioage Labs's Net Margin % or its related term are showing as below:

BIOA's Net Margin % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 4.595
* Ranked among companies with meaningful Net Margin % only.

Bioage Labs Net Margin % Historical Data

The historical data trend for Bioage Labs's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioage Labs Net Margin % Chart

Bioage Labs Annual Data

Trend

Dec22

Dec23

Dec24

Net Margin %

Bioage Labs Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Margin %	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Bioage Labs's Net Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Bioage Labs's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioage Labs's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bioage Labs's Net Margin % distribution charts can be found below:

* The bar in red indicates where Bioage Labs's Net Margin % falls into.

Save Embed

;

Save Embed

;

Bioage Labs Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Bioage Labs's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-71.109	/	0
	=	%

Bioage Labs's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-21.129	/	0
	=	%

Bioage Labs (NAS:BIOA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Bioage Labs Net Margin % Related Terms

Thank you for viewing the detailed overview of Bioage Labs's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioage Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1445A South 50th Street, Richmond, CA, USA, 94804

Website

https://www.bioagelabs.com

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.